Auna SA, a leading healthcare platform in Latin America, reported its financial results for the second quarter of 2025. The company saw a 4% increase in consolidated revenue on a foreign exchange-neutral basis, although on a reported basis, revenue declined by 2% to S/1,094 million. Adjusted EBITDA increased by 5% FXN but decreased 3% year-over-year to S/241 million, with the EBITDA margin remaining steady at 22.1%. Significantly, Auna's adjusted net income rose to S/89 million, a substantial increase from S/13 million in the same quarter of the previous year. This resulted in an adjusted net income per share of S/1.17, based on a weighted average of 74,217,754 shares. The company highlighted positive contributions from its operations in Mexico, Peru, and Colombia, despite challenges from foreign exchange headwinds. In local currency terms, Adjusted EBITDA grew by 2% in Mexico, 8% in Peru, and 9% in Colombia. The results were affected by the depreciation of the Mexican peso and the Colombian peso against the Peruvian sol. Auna's leverage ratio remained stable at 3.6x, and its oncology medical loss ratio reached a record low of 49.8%. The company continues to focus on delivering clinical and operational excellence across its diversified geographic footprint.